Source:http://linkedlifedata.com/resource/pubmed/id/21464372
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
25
|
| pubmed:dateCreated |
2011-6-24
|
| pubmed:abstractText |
The success of reduced intensity conditioning (RIC) transplantation is largely dependent on alloimmune effects. It is critical to determine whether immune modulation with anti-T-cell antibody infusion abrogates the therapeutic benefits of transplantation. We examined 1676 adults undergoing RIC transplantation for hematologic malignancies. All patients received alkylating agent plus fludarabine; 792 received allografts from a human leukocyte antigen-matched sibling, 884 from a 7 or 8 of 8 HLA-matched unrelated donor. Using Cox regression, outcomes after in vivo T-cell depletion (n = 584 antithymocyte globulin [ATG]; n = 213 alemtuzumab) were compared with T cell- replete (n = 879) transplantation. Grade 2 to 4 acute GVHD was lower with alemtuzumab compared with ATG or T cell- replete regimens (19% vs 38% vs 40%, P < .0001) and chronic GVHD, lower with alemtuzumab, and ATG regimens compared with T-replete approaches (24% vs 40% vs 52%, P < .0001). However, relapse was more frequent with alemtuzumab and ATG compared with T cell-replete regimens (49%, 51%, and 38%, respectively, P < .001). Disease-free survival was lower with alemtuzumab and ATG compared with T cell-replete regimens (30%, 25%, and 39%, respectively, P < .001). Corresponding probabilities of overall survival were 50%, 38%, and 46% (P = .008). These data suggest adopting a cautious approach to routine use of in vivo T-cell depletion with RIC regimens.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:ArtzAndrewA,
pubmed-author:ChamplinRichard ERE,
pubmed-author:DevineStevenS,
pubmed-author:EapenMaryM,
pubmed-author:HoVincentV,
pubmed-author:HorowitzMary MMM,
pubmed-author:IsolaLuisL,
pubmed-author:KanFangyuF,
pubmed-author:LazarusHillard MHM,
pubmed-author:LerademacherJenniferJ,
pubmed-author:MarksDavid IDI,
pubmed-author:PorterDavid LDL,
pubmed-author:SoifferRobert JRJ,
pubmed-author:WallerEdmund KEK
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
23
|
| pubmed:volume |
117
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6963-70
|
| pubmed:meshHeading |
pubmed-meshheading:21464372-Adult,
pubmed-meshheading:21464372-Aged,
pubmed-meshheading:21464372-Antibodies,
pubmed-meshheading:21464372-Graft vs Host Disease,
pubmed-meshheading:21464372-Hematologic Neoplasms,
pubmed-meshheading:21464372-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21464372-Humans,
pubmed-meshheading:21464372-Middle Aged,
pubmed-meshheading:21464372-Recurrence,
pubmed-meshheading:21464372-Survival Analysis,
pubmed-meshheading:21464372-T-Lymphocytes,
pubmed-meshheading:21464372-Transplantation Conditioning,
pubmed-meshheading:21464372-Treatment Outcome,
pubmed-meshheading:21464372-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
| pubmed:affiliation |
Dana-Farber Cancer Institute, Boston, MA, USA. Robert_Soiffer@dfci.harvard.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|